Generic LACTITOL INN equivalents, pharmaceutical patent expiration information and freedom to operate

Sponsor	Phase
Post Graduate Institute of Medical Education and Research, Chandigarh	PHASE4
Indian Council of Medical Research	PHASE4
Al-Azhar University	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Braintree Labs	PIZENSY	lactitol	FOR SOLUTION;ORAL	211281-001	Feb 12, 2020		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 4, 2026

Lactitol is a low-cost osmotic laxative with established use outside the United States and a limited branded presence in the U.S. market through Pizensy. The drug’s commercial opportunity is constrained by competition from polyethylene glycol, lactulose, prescription secretagogues, and inexpensive over-the-counter products. Bausch Health has not publicly reported standalone Pizensy revenue, making the product’s financial trajectory difficult to quantify. Its value is primarily tied to niche prescription positioning, payer access, and lifecycle management rather than rapid market expansion.

What is lactitol and how is it used?

Lactitol is a disaccharide osmotic laxative that retains water in the intestinal lumen and increases stool water content. In the United States, Pizensy is approved for chronic idiopathic constipation in adults. The FDA approved Pizensy on February 12, 2019, under New Drug Application 211281. The product is supplied as a powder for oral solution and is administered once daily at a recommended dose of 20 grams. [1]

Pizensy is manufactured and commercialized within Bausch Health’s Salix Pharmaceuticals portfolio. Lactitol is also sold or has been sold in non-U.S. markets under product names including Importal and related regional brands, subject to local approvals and formulations.

Key product attributes

Attribute	Lactitol/Pizensy profile
Active ingredient	Lactitol
U.S. brand	Pizensy
U.S. sponsor	Bausch Health US LLC
FDA approval	February 12, 2019
NDA	211281
Indication	Chronic idiopathic constipation in adults
Dosage form	Powder for oral solution
Recommended dose	20 g once daily
Drug class	Osmotic laxative
Primary commercial alternatives	PEG 3350, lactulose, lubiprostone, linaclotide, plecanatide, prucalopride
Biosimilar relevance	None; lactitol is a small-molecule carbohydrate laxative

The most common adverse reactions in the FDA label are flatulence and diarrhea. The label also includes warnings concerning electrolyte abnormalities and contraindications associated with gastrointestinal obstruction or suspected obstruction. [2]

How large is the lactitol market?

The global lactitol market is fragmented and lacks a single authoritative public revenue database. Commercial market reports often combine lactitol with broader categories such as bulk-forming agents, osmotic laxatives, disaccharide laxatives, or chronic constipation treatments. Reported market estimates therefore vary depending on whether the analysis includes food ingredients, pharmaceutical-grade lactitol, non-U.S. products, and bulk excipient sales.

The pharmaceutical market is smaller than the total lactitol market because lactitol also has applications as a low-calorie sweetener and bulking agent. Pharmaceutical demand is concentrated in Europe, parts of Asia, Latin America, and selected Middle Eastern markets. U.S. prescription demand is limited by the strength of established generic and over-the-counter alternatives.

Principal market segments

Prescription chronic constipation treatment in the United States.
Hospital and retail laxative use outside the United States.
Pharmaceutical-grade lactitol supplied to regional marketers.
Food and nutraceutical applications, including low-calorie formulations.

The commercial economics differ sharply across these segments. Branded prescription lactitol can generate higher revenue per patient but carries sales-force, payer, and market-access costs. Bulk lactitol and generic products have lower unit economics but can benefit from recurring volume and lower promotional requirements.

What drives lactitol demand?

Lactitol demand is supported by several durable factors:

Aging populations with higher constipation prevalence.
Growth in chronic constipation diagnosis and treatment.
Increased use of prescription therapies after failure of dietary measures and over-the-counter laxatives.
Demand for once-daily oral formulations.
Longstanding clinical familiarity with osmotic disaccharides in non-U.S. markets.
Potential use where clinicians prefer an alternative to lactulose or stimulant laxatives.

The main constraint is substitution. PEG 3350 is widely available without a prescription and is commonly used as an initial therapy. Lactulose is inexpensive, established, and broadly available. Prescription drugs such as linaclotide, plecanatide, lubiprostone, and prucalopride compete for patients with persistent symptoms or inadequate response to laxatives.

Clinical guidelines generally place inexpensive osmotic therapies before newer branded prescription medicines for many patients with chronic idiopathic constipation. The American Gastroenterological Association and American College of Gastroenterology recommend PEG and recognize prescription agents for patients who do not respond adequately to over-the-counter therapies. [3]

How does lactitol compare with competing constipation drugs?

Product or class	Typical market position	Commercial strength	Main limitation
Lactitol	Prescription osmotic laxative; established outside the U.S.	Once-daily dosing and established international use	Limited U.S. brand recognition and strong generic substitution
PEG 3350	First-line over-the-counter osmotic laxative	Low cost and broad consumer familiarity	Generic, crowded category
Lactulose	Prescription osmotic disaccharide	Long clinical history and low price	Gas, bloating, taste, and frequent dose adjustment
Linaclotide	Branded prescription secretagogue	Strong efficacy positioning and significant commercial infrastructure	Higher cost and diarrhea risk
Plecanatide	Branded prescription secretagogue	Once-daily prescription option	Smaller commercial base and payer controls
Lubiprostone	Prescription chloride channel activator	Established treatment for selected constipation populations	Nausea and competing branded products
Prucalopride	Prescription 5-HT4 agonist	Prokinetic mechanism and chronic-use positioning	More specialized use and payer restrictions

Lactitol’s strongest positioning is as a palatable, once-daily osmotic option for patients who need a prescription product but do not require a secretagogue or prokinetic. Its weakest position is against low-cost PEG 3350, which has high consumer awareness and no branded acquisition cost.

What is the FDA regulatory status of lactitol?

Pizensy is FDA-approved for chronic idiopathic constipation in adults. It is not a biologic and therefore does not create a biosimilar pathway. Any follow-on product would proceed through a small-molecule abbreviated new drug application, provided the applicant can establish pharmaceutical equivalence, bioequivalence, and applicable regulatory requirements.

Lactitol’s U.S. regulatory history is commercially important because the active ingredient had established international use before its U.S. approval. The 2019 approval created a prescription brand platform, but it did not convert lactitol into a high-barrier specialty medicine.

The FDA label does not indicate a complex delivery system, device, biologic process, or specialized manufacturing platform. That limits the technical barriers to competition.

What patents protect Pizensy and lactitol?

The principal intellectual-property value for Pizensy is more likely to arise from formulation, dosage form, manufacturing, or regulatory exclusivity than from broad composition-of-matter protection over lactitol itself. Lactitol is an established compound with long international use, which reduces the likelihood that a new U.S. product could rely on a durable, late-expiring compound patent comparable to a newly discovered pharmaceutical entity.

Formulation and method-of-use protection

Potential areas of patent protection include:

Powder formulations for oral solution.
Sachet or unit-dose packaging.
Stability and moisture-control systems.
Manufacturing processes for pharmaceutical-grade lactitol.
Methods of treating chronic idiopathic constipation.
Dosing regimens or patient subgroups.

The commercial effect of these rights depends on whether they are listed in the FDA Orange Book, whether they remain unexpired, and whether a generic applicant must address them through a Paragraph IV certification. The FDA’s public approval materials establish the NDA and product approval but do not, by themselves, establish the full scope or current enforceability of any Pizensy patent estate. [1][4]

Orange Book status and Paragraph IV risk

An ANDA applicant seeking approval before expiration of listed patents can certify that a listed patent is invalid, unenforceable, or will not be infringed. That certification can trigger patent litigation under the Hatch-Waxman Act and may create a 30-month stay of approval, subject to statutory conditions. [5]

For lactitol, Paragraph IV risk is structurally lower than for a novel small molecule because:

The active ingredient is old and internationally established.
The dosage form is relatively simple.
The indication is broad and clinically familiar.
PEG 3350 and lactulose provide inexpensive substitutes even without a generic Pizensy launch.
The commercial value may not justify prolonged litigation unless Pizensy prescriptions reach a meaningful scale.

A definitive patent-by-patent Orange Book conclusion requires the operative FDA listing at the relevant date. Public FDA approval records alone do not establish that every formulation or method patent remains listed, valid, or commercially enforceable.

When does lactitol lose exclusivity?

Pizensy’s U.S. market protection consists of regulatory exclusivity, any applicable listed patents, and practical brand advantages. The FDA approval date was February 12, 2019. If five-year new chemical entity exclusivity applied, the earliest ANDA approval date would have been February 12, 2024, subject to applicable regulatory conditions. If the product received three-year new clinical investigation exclusivity instead, the relevant period would have ended in February 2022. [1][6]

The exact exclusivity category is important because it determines whether an ANDA could be filed and when the FDA could approve it. Lactitol’s prior non-U.S. use does not alone determine U.S. exclusivity. The FDA evaluates the U.S. regulatory history and statutory criteria.

Exclusivity timeline

Event	Date or status
U.S. FDA approval of Pizensy	February 12, 2019
Possible five-year NCE barrier	Through February 12, 2024, if applicable
Possible three-year clinical-investigation period	Through February 12, 2022, if applicable
Patent-based entry date	Depends on listed patents and litigation
Generic entry after approval	Depends on ANDA approval, certifications, and settlement terms
International lactitol availability	Established before U.S. approval in several markets

There is no single “lactitol exclusivity expiration date” that captures the full commercial picture. Regulatory exclusivity, patent expiry, ANDA approval, and settlement rights can produce different entry dates.

Which companies are challenging or competing with Pizensy?

The most important competitive threat does not come from a single named generic challenger. It comes from established constipation products with lower prices and greater market familiarity.

Competitive groups

Generic PEG 3350 manufacturers and retailers.
Lactulose manufacturers.
Branded secretagogue companies, including AbbVie through Linzess and Synergy Pharmaceuticals’ former Trulance business now associated with Bausch’s gastrointestinal portfolio.
Lubiprostone suppliers.
Prucalopride marketers.
Regional lactitol manufacturers outside the United States.

Public disclosures do not identify a major lactitol-specific Paragraph IV challenger with the commercial visibility of generic challengers to blockbuster drugs. The more immediate risk to Pizensy is therapeutic substitution, particularly by PEG 3350 and lactulose.

What litigation affects lactitol?

Lactitol does not have a widely reported, high-value U.S. patent litigation profile comparable to major branded medicines. The principal potential litigation pathway would be a Hatch-Waxman action involving an ANDA applicant and any Orange Book-listed Pizensy patents.

No prominent settlement agreement involving a major Pizensy generic launch is identified in the FDA approval materials or the cited public corporate disclosures. The absence of a widely disclosed settlement supports the view that Pizensy has not generated the type of litigation-driven market event seen in larger chronic-care franchises.

Patent risk should still be evaluated at the claim level. A narrow formulation patent may delay one generic product while leaving the underlying therapeutic category exposed to substitution from other laxatives.

How strong is the lactitol patent estate?

The lactitol patent estate appears commercially moderate to weak relative to protected novel medicines, although individual formulation claims could retain value. The main reasons are the age of the active ingredient, the simplicity of oral powder delivery, the broad availability of alternatives, and the absence of a biologic or device-related manufacturing barrier.

Patent-strength factor	Assessment
Compound novelty	Low
Formulation complexity	Low to moderate
Delivery-system barriers	Low
Manufacturing know-how	Moderate for quality and scale, but not necessarily exclusionary
Method-of-use differentiation	Moderate if claims are narrow and clinically supported
Substitution risk	High
Litigation value	Likely limited unless product sales increase materially

Manufacturing know-how can still affect supply reliability. Pharmaceutical-grade lactitol requires control of purity, residual materials, particle characteristics, moisture, and microbiological quality. Those requirements create operating barriers but are unlikely to prevent a capable generic or contract manufacturer from entering the market.

What is the financial trajectory for Pizensy and lactitol?

Bausch Health does not generally report Pizensy revenue as a separate material line item in its consolidated public reporting. The product is part of the Salix portfolio, which includes larger gastrointestinal brands. As a result, investors cannot reliably derive Pizensy sales, gross margin, prescription volume, or contribution profit from Bausch’s consolidated disclosures alone. [7]

Financial trajectory

Period	Commercial interpretation
2019 launch	U.S. entry established a branded prescription market
2020-2021	Launch affected by limited category differentiation and COVID-era prescribing disruption
2022-2024	Increasing exposure to generic-entry risk if applicable exclusivity periods expired
Post-exclusivity period	Revenue depends on payer coverage, brand retention, supply, and absence of approved generics
Long term	Likely niche product economics rather than blockbuster growth

Pizensy can generate value without reaching blockbuster scale if it has favorable manufacturing costs, stable reimbursement, and cross-selling support within the Salix gastrointestinal portfolio. Its revenue ceiling is constrained by the low price of PEG 3350 and lactulose, which limits payer willingness to reimburse a premium.

The most likely financial profile is a modest branded product with relatively predictable demand among prescribers who prefer a prescription osmotic laxative. Significant upside would require one or more of the following:

Strong formulary access.
Evidence of better tolerability or adherence than lactulose.
Expansion into additional constipation populations.
International licensing or regional distribution.
A favorable generic-entry outcome.
Bundling with a broader gastrointestinal sales platform.

What licensing deals affect lactitol?

No major lactitol-specific licensing transaction is identified in the cited public materials. Lactitol’s international distribution has historically involved regional manufacturers and marketers, but those arrangements are distinct from a high-value global licensing deal.

The most relevant strategic transaction for Pizensy is Bausch Health’s ownership of Salix, which provides commercial infrastructure, gastroenterology relationships, and portfolio-level promotion. That structure can reduce standalone selling costs but also makes it difficult to isolate Pizensy’s individual financial contribution.

Potential licensing value is higher outside the United States, where lactitol has longer commercial history and where local manufacturers may already have distribution channels. U.S. licensing value is lower because the product competes against low-cost generic laxatives.

What generic launch scenarios exist for lactitol?

Scenario 1: No approved generic in the near term

Pizensy retains a niche prescription position. Revenue declines gradually as prescribers substitute toward cheaper alternatives, but the brand remains available for patients who prefer its formulation or whose plans cover it.

Scenario 2: Single generic entrant

A first approved generic could produce a sharp reduction in branded market share, followed by price erosion. Pizensy might retain limited share through contracting, patient support, or physician familiarity.

Scenario 3: Multiple generic entrants

This would create rapid price compression and reduce the value of the brand. The market would likely converge toward commodity economics, with supply reliability and manufacturing cost becoming more important than clinical differentiation.

Scenario 4: Patent settlement with delayed entry

A settlement could preserve branded revenue for a defined period while granting the challenger a negotiated launch date. The economic value would depend on the entry date, authorized-generic provisions, and any restrictions on launch quantities.

What is the commercial outlook for lactitol?

Lactitol has a stable therapeutic rationale but limited pricing power. Its strongest commercial attributes are once-daily dosing, established international use, and a prescription option for chronic idiopathic constipation. Its weaknesses are low clinical differentiation, low-cost alternatives, and limited visibility into standalone brand performance.

The product is best viewed as a niche gastrointestinal asset. Its financial trajectory is more likely to reflect gradual erosion or stable low-level demand than rapid growth. The main variables are generic approval, Orange Book-listed patents, payer coverage, Bausch’s promotional allocation, and international sales.

Key Takeaways

Pizensy is the FDA-approved U.S. lactitol product for chronic idiopathic constipation in adults.
FDA approval occurred on February 12, 2019, under NDA 211281.
Lactitol competes primarily with PEG 3350 and lactulose, not only with branded prescription drugs.
Bausch Health does not publicly disclose standalone Pizensy revenue in its principal financial reporting.
Lactitol has no biosimilar pathway because it is a small-molecule carbohydrate laxative.
The commercial patent position is more likely to depend on formulation, method-of-use, and regulatory exclusivity than on compound protection.
Generic-entry risk is meaningful because the product uses a relatively simple oral powder dosage form.
No major lactitol-specific licensing transaction or high-profile Paragraph IV litigation is identified in the cited public materials.
The likely long-term outcome is niche prescription demand with limited pricing power and substantial substitution pressure.

FAQs

Is lactitol the same as lactulose?

No. Both are nonabsorbable osmotic disaccharides, but lactitol and lactulose are different active ingredients. Lactulose has longer and broader use in the United States, including constipation and hepatic encephalopathy indications.

Is Pizensy available over the counter?

Pizensy is an FDA-approved prescription product. Over-the-counter lactitol availability is not equivalent to the U.S. prescription status of Pizensy.

Does lactitol compete with MiraLAX?

Yes. MiraLAX contains PEG 3350 and is one of the most important commercial substitutes for lactitol in the United States. Its OTC availability and low price create substantial pressure on Pizensy.

Can lactitol be used in children?

Pizensy’s FDA-approved indication is for adults with chronic idiopathic constipation. Pediatric use requires separate clinical and regulatory evaluation and should not be inferred from the adult label.

Is lactitol attractive for pharmaceutical investors?

Lactitol is more consistent with a niche, cash-generative gastrointestinal product than a high-growth pharmaceutical asset. Investment value depends on acquisition price, manufacturing cost, payer coverage, generic timing, and the ability to leverage an existing gastroenterology sales platform.

References

U.S. Food and Drug Administration. (2019). FDA approves Pizensy for chronic idiopathic constipation in adults. FDA.
U.S. Food and Drug Administration. (2024). Pizensy (lactitol) prescribing information. FDA.
American Gastroenterological Association & American College of Gastroenterology. (2023). Clinical practice guideline for pharmacological management of chronic idiopathic constipation. Gastroenterology, 164(7), 1086-1106.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
U.S. Food and Drug Administration. (2024). Small business and industry assistance: Exclusivity and patent provisions. FDA.
Bausch Health Companies Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Bausch Health.

US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	4
Raw Ingredient (Bulk) Api Vendors:	51
Clinical Trials:	7
What excipients (inactive ingredients) are in LACTITOL?	LACTITOL excipients list
DailyMed Link:	LACTITOL at DailyMed

Summary for LACTITOL

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LACTITOL

Recent Clinical Trials for LACTITOL

Anatomical Therapeutic Chemical (ATC) Classes for LACTITOL